Durvalumab/Infinifer combination chemotherapy regimen

Durvalumab/Infinifer (Durvalumab) has gradually improved its status in the field of immunotherapy, the most representative of which is its combined application with chemotherapy. Compared with single-agent immunotherapy, the combination of immunological drugs and chemotherapy drugs can produce a synergistic effect, making the anti-tumor treatment effect more significant. By directly killing tumor cells, chemotherapy can not only reduce tumor burden, but also change the tumor microenvironment, thereby enhancing the sensitivity of immunotherapy. Imrvalumab restores T cell function by blocking the PD-L1 pathway, allowing the body's immune system to continue to monitor residual cancer cells for a long time on the basis of chemotherapy clearing some tumor cells. This dual role shows good clinical prospects.

Currently, the most common indications for durvalumab combined with chemotherapy are small cell lung cancer, non-small cell lung cancer, etc. Especially in the initial treatment of extensive-stage small cell lung cancer, this regimen has been recommended as a first-line treatment option by multinational guidelines. In this type of regimen, durvalumab is usually used in combination with platinum drugs and etoposide to form an immune combination chemotherapy model, which not only improves the survival time of patients, but also shows positive effects in delaying drug resistance. For patients with non-small cell lung cancer, durvalumab combined with platinum-based chemotherapy also shows the potential to improve efficacy, especially in the consolidation and maintenance phase after chemoradiotherapy.

There are a large number of international clinical studies supporting the application prospects of durvalumab combined with chemotherapy, which is one of the key reasons for its rapid approval by regulatory agencies. It should be emphasized that although combination therapy has significant efficacy, the adverse reactions are relatively complex, including immune-related adverse events and chemotherapy-related toxic reactions. Clinicians need to conduct careful monitoring and management during application.

Reference materials:https://www.imfinzi.com/